3 and the structurally related pituitary adenylate cyclase-activating polypeptide (PACAP), two neuropeptides present in the lymphoid microenvironment, elicit a broad spectrum of biological functions, including the modulation of innate and adaptive immunity (reviewed in Refs. 1-5). VIP and PACAP down-regulate the innate response, by inhibiting inducible NO synthase expression and secretion of proinflammatory cytokines in stimulated macrophages (6 -11). VIP and PACAP affect the adaptive T cell response indirectly, by down-regulating B7.1/B7.2 expression and the subsequent costimulatory function of activated macrophages (12). In addition, the two neuropeptides also affect TCR-stimulated T cells directly, by inhibiting IL-2 production and cell proliferation (reviewed in Ref. 20) , and NF-B (21-24) are essential for FasL expression and subsequent apoptosis in activated T cells. In addition, it has been reported that early growth factors (Egr) 2 and 3, two members of the early growth-response family of transcriptional factors, are required for optimal FasL gene transcription (25, 26) .
V asoactive intestinal peptide (VIP) 3 and the structurally related pituitary adenylate cyclase-activating polypeptide (PACAP), two neuropeptides present in the lymphoid microenvironment, elicit a broad spectrum of biological functions, including the modulation of innate and adaptive immunity (reviewed in Refs. [1] [2] [3] [4] [5] . VIP and PACAP down-regulate the innate response, by inhibiting inducible NO synthase expression and secretion of proinflammatory cytokines in stimulated macrophages (6 -11) . VIP and PACAP affect the adaptive T cell response indirectly, by down-regulating B7.1/B7.2 expression and the subsequent costimulatory function of activated macrophages (12) . In addition, the two neuropeptides also affect TCR-stimulated T cells directly, by inhibiting IL-2 production and cell proliferation (reviewed in Ref. 2) . Another important immunoregulatory function of VIP and PACAP is their effect on activation-induced cell death (AICD) in T cells. We reported recently that VIP and PACAP inhibit AICD in peripheral T cells, particularly in the CD4 ϩ subset (13) . Apoptosis of activated T cells represents an important mechanism for the maintenance of immune homeostasis, and is mediated primarily through Fas ligand (FasL)/Fas interactions (reviewed in Ref. 14) . In contrast to Fas, which is constitutively expressed in T cells, FasL expression is induced following activation. Engagement of Fas by FasL leads to Fas oligomerization and generation of apoptotic signals in the Fas-bearing targets (reviewed in Ref. 15 ). The inhibition of AICD in peripheral T cells by VIP and PACAP is mediated through the down-regulation of FasL expression (13) . The purpose of the present study was to investigate the molecular mechanisms by which VIP and PACAP control FasL expression in T cells.
Expression of FasL following TCR stimulation involves various transcriptional factors. Several reports indicated that c-Myc (16 -18) , NF-AT (19, 20) , and NF-B (21) (22) (23) (24) are essential for FasL expression and subsequent apoptosis in activated T cells. In addition, it has been reported that early growth factors (Egr) 2 and 3, two members of the early growth-response family of transcriptional factors, are required for optimal FasL gene transcription (25, 26) .
In the present study, we determined that VIP and PACAP inhibit TCR-stimulated FasL expression and apoptosis of 2B4.11 T cell hybridoma through specific receptors and induction of intracellular cAMP. VIP and PACAP down-regulate c-Myc synthesis, the NF-AT-dependent Egr2 and Egr3 expresion, and the nuclear translocation and DNA binding of NF-AT and NF-B.
Materials and Methods

Reagents
Synthetic VIP and PACAP38 were purchased from Novabiochem (Laufelfingen, Switzerland). The PACAP receptor (PAC1)/type 2 VIP receptor (VPAC2) antagonist PACAP 6 -38 was obtained from Peninsula Laboratories (Belmont, CA). mAbs to murine FasL (CD95L, MFL3), and CD3⑀ (145-2C11) were purchased from PharMingen (San Diego, CA).
Induction of apoptosis
For induction of apoptosis, 2B4.11 cells (5 ϫ 10 5 /ml) were cultured in 96-well plates (Corning Glass, Corning, NY) with immobilized anti-CD3 mAb (1 g/ml), or with PMA (10 ng/ml) and ionomycin (1 g/ml), in the presence or absence of VIP, PACAP, VIP/PACAP receptor antagonists, and other agents, as described in text. Apoptosis was determined at 24 h, as described below.
Assessment of cell viability and apoptosis
Cell viability was assessed by trypan blue exclusion and loss of mitochondrial function with the MTT staining method. For MTT staining, 100 l of culture was placed in one well of a 96-well tissue culture plate, and 10 l of MTT solution (2.5 mg/ml) was added. After incubation at 37°C for 4 h, 100 l of acid-isopropanol (0.04 N HCl in isopropanol) was added and mixed by gently pipetting, and the OD 560 nm was assessed with an ELISA reader.
Apoptosis was assessed by TUNEL assay, using a fluorescein in situ cell death detection kit (Boehringer Mannheim, Indianapolis, IN), according to the manufacturer's instructions. Briefly, at the various time points, 1 ϫ 10 6 T cells were harvested and fixed in 1% formaldehyde for 15 min on ice, washed with PBS, and stored in 70% ethanol at 4°C. For analysis, the cells were washed and incubated with 50 l primary buffer (0.2 M potassium cacodylate, 25 mM Tris-HCl, pH 6.6, 2.5 mM cobalt chloride, 0.25 mg/ml BSA, 100 U/ml TdT, and 10 mM biotin-16-dUTP) for 30 min at 37°C. Washed samples were resuspended in 100 l of secondary buffer (2.5 g/ml FITC-streptavidin, 0.1% Triton X-100, and 5% nonfat dry milk in 4ϫ saline sodium citrate buffer (Sigma)). After incubation at room temperature in the dark for 30 min, the apoptotic cells were identified as FITC positive by flow cytometry using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
DNA fragmentation was assessed by agarose gel electrophoresis. After culture for the indicated times, 5 ϫ 10 5 cells were harvested and centrifuged at 750 ϫ g for 10 min, resuspended in 100 l hypotonic lysis buffer A (100 mM Tris-HCl, 40 mM EDTA pH 8, 0.8% sodium lauryl sarcosinate, and 0.5 mg/ml proteinase K), incubated at 50°C for 4 h, followed by the addition of RNase to a final concentration of 0.2 mg/ml. After incubation at 37°C for another 30 min, the resulting DNA fragments were precipitated with 0.5 mM NaCl and 1 vol of isopropanol at Ϫ20°C overnight. The samples were centrifuged at 14,000 ϫ g for 20 min at 4°C, and the pellets were washed with 70% ethanol and allowed to dry at room temperature. The DNA resuspended in TE solution (10 mM Tris-HCl, 1 mM EDTA, pH 7.4) was fractionated by agarose gel electrophoresis and visualized under UV light after staining with ethidium bromide.
FACS analysis
The 2B4.11 T cells (1 ϫ 10 6 cells/ml) stimulated in 96-well plates under conditions indicated in text were harvested in ice-cold RPMI complete medium and washed twice with PBS containing 0.1% sodium azide plus 2% heat-inactivated FCS (wash buffer). The cells were incubated in wash buffer containing 2.5 g/ml normal mouse Ig for 15 min, followed by anti-FasL (MFL3) mAb (2.5 g/ml) and incubation at 4°C for 1 h. Isotypematched mouse Abs were used as controls, and IgG block (Sigma) was used to block the nonspecific binding of the mAb to FcR. The cells were washed and further stained with 2.5 g/ml of FITC-conjugated goat F(abЈ) 2 anti-hamster IgG (Sigma) for 30 min at 4°C. After extensive washing, cells were fixed in 1% buffered paraformaldehyde. Stained lymphocytes, gated according to scatter characteristics, were analyzed with a FACScan flow cytometer (Becton Dickinson). Fluorescence data are expressed as mean channel fluorescence and as percentage of positive cells after subtraction of background isotype-matched values.
Analysis of functional FasL expression
Activation-induced FasL expression on the anti-CD3-stimulated 2B4.11 T cells was assessed by determining the ability of these cells to cause lysis of Fas ϩ target cells, as described previously (20) . Briefly, 2B4.11 T cells were activated with immobilized anti-CD3 mAbs in the presence or absence of VIP or PACAP (10 Ϫ8 M) for 8 h to allow FasL expression. After washing twice, the 2B4.11 T cells were resuspended in complete medium, and added to the wells of a 96-well V-bottom microtiter plate (Corning) in graded dilutions to obtain the desired E:T ratio. The target cells, L1210 (wild type) or L1210-Fas ϩ cells (10 6 cells/ml), were labeled for 2 h at 37°C with 150 Ci of sodium [ 51 Cr]chromate (Amersham), washed three times with PBS/5% FCS, resuspended in complete medium, and added to the microtiter plates at a concentration of 1 ϫ 10 4 cells/well. In other experiments, VIP and PACAP were added directly to the cocultures to determine their effects on Fas-mediated lysis. The plates were incubated overnight at 37°C and 5% CO 2 , then centrifuged, and a 100-l aliquot of the supernatant was removed for measurement in a Beckman gamma 8000 counter (Beckman, Fullerton, CA). The percent lysis was determined as follows: % lysis ϭ (E Ϫ S)/(M Ϫ S) ϫ 100, in which E is the release from experimental samples, S is the spontaneous release, and M is the maximum release upon lysis with 10% SDS.
RNA extraction and Northern blot analysis
Northern blot analysis was performed according to standard methods. The 2B4.11 cells were prepared and stimulated as described above. At the various time points, 1 ϫ 10 7 cells were harvested and total RNA was extracted by the acid guanidinium-phenol-chloroform method, electrophoresed on 1.2% agarose-formaldehyde gels, transferred to S&S Nytran membranes (Schleicher & Schuell, Keene, NJ), and cross-linked to the nylon membrane using UV light.
The probes for murine FasL, c-myc, egr2, egr3, and GAPDH were generated by RT-PCR, as described previously, using the following primers: FasL, 5Ј-TCACCAACCAAAGCCTTAAAGTAT-3Ј and 5Ј-TCAAC CTCTTCTCCTCCATTAGCA-3Ј; c-myc, 5Ј-ACAGAGGGAGTGAGC GGACG-3Ј and 5Ј-TTCACGTTGAGGGGCATCG-3Ј; egr2, 5Ј-GG TGACCATCTTTCCCAATGCC-3Ј and 5Ј-CTCCTGCACAGCCAGAAT AAGGA-3Ј; egr3, 5Ј-GTCTGACCAACGAGAAGCCCAA-3Ј and 5Ј-AGGCCGG CTTGGCCGATTGGTA-3Ј; and GAPDH, 5Ј-TCCTGC ACCACCAACTGCTTAG CC-3Ј and 5Ј-GTTCAGCTCTTGGATGACC TTGCC-3Ј. Oligonucleotides were end labeled with [␥-32 P]dATP (3000 Ci/mmol; Amersham, Arlington, IL) by using T4 polynucleotide kinase. The RNA-containing membranes were prehybridized for 16 h at 42°C, and hybridized at 60°C for 16 h with the appropriate probes. The membranes were then washed twice in 2ϫ SSC containing 0.1% SDS at room temperature (20 min each time), once at 37°C for 20 min, and once in 0.1ϫ SSC containing 0.1% SDS at 50°C (20 min). The prehybridization and hybridization buffers were purchased from 5Ј Prime33Ј Prime (Boulder, CO). The membranes were exposed to x-ray films (Kodak, Rochester, NY). Signal quantitation was performed in a PhosphorImager SI (Molecular Dynamics, Sunnyvale, CA).
EMSA
Nuclear extracts were prepared by the mini-extraction procedure of Schreiber et al. (30) with slight modifications. The 2B4.11 cells were cultured at a density of 10 7 cells in six-well plates, stimulated with anti-CD3 as described above, washed twice with ice-cold PBS/0.1% BSA, and harvested. The cell pellets were homogenized with 0.4 ml of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, and 1 mM NaN 3 ). After 15 min on ice, Nonidet P-40 was added to a final 0.5% concentration, the tubes were gently vortexed for 15 s, and nuclei were sedimented and separated from cytosol by centrifugation at 12,000 ϫ g for 40 s. Pelleted nuclei were washed once with 0.2 ml of ice-cold buffer A, and the soluble nuclear proteins were released by adding 0.1 ml of buffer C (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 25% glycerol, 1 mM DTT, 0.5 mM PMSF, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, and 1 mM NaN 3 ). After incubation for 30 min on ice, followed by centrifugation for 10 min at 14,000 rpm at 4°C, the supernatants containing the nuclear proteins were harvested, the protein concentration was determined by the Bradford method, and aliquots were stored at Ϫ80°C for later use in EMSAs.
Oligonucleotides corresponding to the proximal NF-B site (Ϫ138/ Ϫ128, 5Ј-GAGAAAGGTGTTTCCCTTGAC-3Ј), NF-AT (Ϫ246/Ϫ229, 5Ј-CTGGGCGGAAACTTCCTG-3Ј), and FasL regulatory element (FLRE) motif (Ϫ220/Ϫ205, 5Ј-AAGTGAGTGGGTGTTT-3Ј) of the murine FasL promoter, and to the NF-AT site (Ϫ134/Ϫ108, 5Ј-TAATGTTC CATTGTGAGGAGCTTCCAT-3Ј) of the murine egr3 promoter were synthesized and annealed. Aliquots of 50 ng of the double-stranded oligonucleotides were end labeled with [␥-32 P]ATP by using T4 polynucleotide kinase. For EMSAs with hybridoma nuclear extracts, 20,000 -50,000 cpm of double-stranded oligonucleotides, corresponding to ϳ0.5 ng, were used for each reaction. The binding reaction mixtures (15 l) consisted of: 0.5-1 ng DNA probe, 5 g nuclear extract, 2 g poly(dI-dC)⅐poly(dI-dC), and binding buffer (50 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 5% glycerol, and 10 mM Tris-HCl, pH 7.5). The mixtures were incubated on ice for 15 min before adding the probe, followed by another 20 min at room temperature. Samples were loaded onto 4% nondenaturing polyacrylamide gels and electrophoresed in TGE buffer (50 mM Tris-HCl, pH 7.5, 0.38 M glycine, and 2 mM EDTA) at 100 V, followed by transfer to Whatman paper, drying under vacuum at 80°C, and autoradiography. In competition and Ab supershift experiments, the nuclear extracts were incubated for 15 min at room temperature with the specific Ab (1 g) or competing cold oligonucleotide (50-fold excess) before the addition of the labeled probe.
RT-PCR for the detection of VPAC1, VPAC2, and PAC1 mRNA
Total RNA was isolated from unstimulated and anti-CD3-stimulated 2B4.11 T cells (1 ϫ 10 7 cells) using the Ultraspec RNA reagent (Biotecx, Houston, TX), as recommended by the manufacturer. Two micrograms of total RNA were reverse transcribed in the presence of 200 U Moloney murine leukemia virus reverse transcription, 40 U RNasin, 1 g random primers, 0.5 mM dNTPs, 3 g BSA, and Moloney murine leukemia virus reaction buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 ) in a total volume of 30 l at 37°C for 1 h.
The cDNA were amplified with specific primers. Amplification with ␤-actin primers was used as a control. The primers for VPAC1, VPAC2, and PAC1 receptors have been described before (9, 13) , and have the following sequence: VPAC1 sense, 5Ј-CCTTCTTCTCTGAGCGGAAG TACTT-3Ј, and antisense, 5Ј-CCTGCACCTCACCATTGAGGAAGCAG-3Ј; VPAC2 sense, 5Ј-GTCAAGGACAGCGTGCTCTACTCC-3Ј, and antisense, 5Ј-CCTTACAATGCTGATGAAGAGGGC-3Ј; PAC1 sense, 5Ј-CAAGAAGGAGCAAGCCATGTGC-3Ј, and antisense, 5Ј-CATCGAGT AATGGGGGAAGGG-3Ј; ␤-actin sense, 5Ј-GATGGTGGGTATGGGTC AGGGG-3Ј, and antisense, 5Ј-GCTCATTGCCGATAGTGATGACCT-3Ј. The expected sizes for the amplified fragments are: 450 bp for VPAC1, 572 bp for VPAC2, 317 bp for PAC1, and 660 bp for ␤-actin. Specific fragments were previously amplified with these primers in macrophages (VPAC1, VPAC2, and PAC1) (9) and T cells (VPAC1 and VPAC2) (13) . Five microliters of reverse-transcribed cDNA were subjected to PCR in the presence of 0.5 U of pyrostase, 1 M sense and antisense primers, 0.2 mM dNTPs, and polymerase buffer (50 mM Tris-HCl, pH 9, 1.5 mM MgCl 2 , 20 mM (NH 4 ) 2 SO 4 , 50 g/ml BSA). The PCR conditions were: denaturation, 94°C, 45 s; annealing, 55°C, 45 s; primer extension, 72°C, 90 s for 35 cycles. The PCR products were size separated on 2% agarose gels and visualized by UV light.
Western blot
Lysates, cytoplasmic fraction, or nuclear extract (see above) containing 20 -30 g of protein were subjected to reducing SDS-PAGE (12.5%). After electrophoresis, the gel was electroblotted in Tris-glycine buffer containing 40% methanol onto a reinforced nitrocellulose membrane (Schleicher & Schuell). The membrane was blocked with TBS-T buffer (10 mM Tris, pH 8, 150 mM NaCl, 0.05% Tween 20) containing 5% milk powder for 1 h at room temperature, then incubated with primary Abs: rabbit antimouse IgG against I-B␣ (1:250), IKK␣ (1:1000), NF-B p50 (1:1000), NF-B p65 (1:1000), Egr1 (1:1000), Egr2 (1:500), Egr3 (1:500), NF-ATp (1:500), or c-Myc (1.5 g/ml), or with mouse IgG against phosphorylated I-B␣ (1:500), in TBS-T containing 1% milk powder for 2 h at room temperature. The membrane was washed with TBS-T, and incubated with secondary Ab: peroxidase-conjugated goat anti-rabbit IgG or rat antimouse IgG at 1/5000 dilution for 1 h at room temperature. After washing three times in TBS-T for 5 min each, and once in TBS for 5 min, the membrane was dried briefly and subjected to the ECL detection system (Amersham). The x-ray films were exposed for 5-20 min. FIGURE 1. VIP and PACAP decrease AICD in the murine T cell hybridoma 2B4.11. A, VIP and PACAP decrease AICD. The 2B4.11 cells (5 ϫ 10 4 cells) were activated with immobilized anti-CD3 mAbs (1 g/ ml), or with PMA (10 ng/ml) plus ionomycin (1 g/ml), in the presence or absence of VIP or PACAP (10 Ϫ8 M). Cells cultured in uncoated plates (unstimulated) were used as control. At different times, apoptosis and cell viability were determined by TUNEL and MTT assay, respectively. Each result is the mean Ϯ SD of four separate experiments performed in duplicate. B, Dose-dependent effect of VIP and PACAP. The 2B4.11 cells (2 ϫ 10 6 cells) were activated with immobilized anti-CD3 mAbs (1 g/ml) in the presence or absence of different concentrations of VIP or PACAP. Genomic DNA fragmentation was assessed by gel electrophoresis at 12 h. One representative experiment of three is shown.
IKK␣ immunoprecipitation and kinase assay
Cell lysates were prepared from 2 ϫ 10 6 cells in 200 l lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM EGTA, 50 mM glycerol phosphate, 1% Triton X-100, 10% glycerol, 1 mM DTT, 2 g/ml leupeptin, 5 g/ml aprotinin, 1 mM PMSF, 5 mM NaF, 10 mM p-nitrophenyl phosphate, and 1 mM Na 3 VO 4 ). The cell lysates were kept on ice and vigorously vortexed every 5 min for 20 min. The lysate was cleared by centrifugation at 13,000 ϫ g for 3 min, and the supernatant was stored at Ϫ80°C. Endogenous IKK␣ was immunoprecipitated from 150 -250 g of cell lysate by incubation with 0.5 g of anti-IKK␣ Ab for 2 h at 4°C. The immune complexes were collected by incubation with protein A/G-Sepharose beads (Sigma) for 45 min at 4°C. The beads were extensively washed with lysis buffer, twice with LiCl buffer (500 mM LiCl, 100 mM Tris-HCl, pH 7.6, and 0.1% Triton X-100), and twice with kinase buffer (20 mM MOPS, pH 7.6, 2 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 0.1% Triton X-100, 1 mM p-nitrophenyl phosphate, and 1 mM Na 3 VO 4 ). The pelleted beads were resuspended in 30 l kinase buffer with 15 M of ATP, 10 Ci of [␥-
32 P]ATP (3000 Ci/mmol), containing 5 g of rI-B␣. The kinase reaction was performed at 30°C for 30 min, and stopped by the addition of 15 l of 2ϫ SDS sample buffer. Samples were boiled for 5 min and subjected to 9% SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane (Schleicher-Schuell), followed by autoradiography. The IKK␣ kinase activity was determined by incorporation of 32 P into its substrate (rI-B␣-tagged fusion protein). The phosphorylated proteins were quantitated by a PhosphorImager. Expression of the IKK␣ was verified by immunoblotting of cell lysates, as described above.
Calcineurin assay
The calcineurin (CaN) phosphatase activity was assayed in whole cellular protein extracts by using the Biomol Green Cellular Calcineurin Assay Kit Plus (Biomol Research Laboratories, Plymouth Meeting, PA), according to the manufacturer's instructions.
Results
VIP and PACAP decrease AICD in T cell hybridomas
As previously reported (27, 28, 31, 32) , the 2B4.11 T cell hybridoma undergoes apoptosis following cross-linking of the TCR/CD3 complex by immobilized anti-CD3 Abs, or following activation with PMA plus ionomycin (Fig. 1A) . The presence of VIP and PACAP during TCR stimulation decreases apoptosis at all times assayed (Fig. 1A) . The neuropeptides inhibit the DNA fragmentation characteristic of TCR-induced apoptosis in a dose-dependent manner (Fig. 1B) . CsA, previously shown to inhibit AICD (33), was used as positive control (Fig. 1B) .
The effect of VIP and PACAP is mediated through the VPAC2 receptor
The immunological actions of VIP and PACAP are exerted through a family of VIP/PACAP receptors, i.e., VPAC1 and VPAC2, which exhibit similar affinities for the two neuropeptides, and PAC1, which exhibits a 300-to 1000-fold higher affinity for PACAP than for VIP (34) . As reported for several T cell lines (13, 35) , the 2B4.11 cells express only VPAC2 (Fig. 2A) . The involvement of VPAC2 in the effect of VIP/PACAP on AICD was established by using specific agonists and antagonists. The VPAC2 agonist, but not the VPAC1 or the PAC1 agonist, inhibited anti-CD3-induced apoptosis of 2B4.11 cells (Fig. 2B ). In addition, PACAP 6 -38 , an antagonist specific for PAC1 and to a lesser degree for VPAC2, but not the specific VPAC1 antagonist (13) , reversed the effects of VIP and PACAP (Fig. 2C) . These results indicate that VIP and PACAP exert their action through VPAC2.
VIP and PACAP inhibit activation-induced FasL expression
AICD in T cell hybridomas proceeds via expression of FasL and subsequent Fas/FasL interaction. We have recently reported that VIP and PACAP reduce FasL expression in activated peripheral T cells (13) . In this study, 2B4.11 T cells were stimulated with immobilized anti-CD3 Abs in the presence or absence of VIP or PACAP, and the expression of FasL was assayed at the protein and mRNA level by flow cytometry and Northern blot, respectively. Activation-induced expression of FasL was greatly reduced in a time-and dose-dependent manner by VIP and PACAP, with an almost complete inhibition in the concentration range of 10 Ϫ8 -10 Ϫ6 M (Fig. 3A) .
To determine whether the inhibition of AICD correlates with the decrease in FasL expression induced by VIP and PACAP, we used a functional assay. The 2B4.11 T cells were incubated with immobilized anti-CD3 Abs for 8 h to induce FasL expression, in the presence or absence of VIP or PACAP. The anti-CD3-treated 2B4.11 cells were incubated with 51 Cr-labeled Fas-bearing target cells (L1210-Fas ϩ cells). In the absence of CD3 cross-linking, no functional FasL is expressed, as indicated by the lack of Fas ϩ -target lysis (Fig. 3B, unstimulated) . In contrast, 2B4.11 cells treated with anti-CD3 Abs lysed the Fas ϩ , but not the Fas Ϫ (L1210-wild type) targets (Fig. 3B ). VIP and PACAP added at the initiation of anti-CD3 treatment (time 0) inhibit in a dose-dependent fashion the lysis of L1210-Fas ϩ cells (Fig. 3B) . In contrast, the addition of VIP or PACAP to cocultures of L1210-Fas ϩ target cells and activated 2B4.11 cells (8 h after activation) failed to inhibit lysis in Fas ϩ targets (Fig. 3C ). This suggests that VIP and PACAP inhibit AICD by preventing FasL expression and not by blocking the Fas signaling pathway.
cAMP as a second messenger for the inhibition of AICD and FasL expression by VIP and PACAP
VPAC2 induces intracellular cAMP as a secondary messenger (reviewed in Ref. 36 ). Therefore, we investigated the role of cAMP in the inhibition of AICD. First, we determined the effects of forskolin (a cAMP-inducing agent) and dbcAMP (a cAMP analogue) on FasL expression and apoptosis in 2B4.11 T cells. Similar to VIP and PACAP, forskolin and dbcAMP inhibit both FasL expression and apoptosis in anti-CD3-stimulated 2B4.11 cells (Fig. 4A) . The role of cAMP as second messenger is supported by the fact that the protein kinase A (PKA) inhibitor H89 reverses in a dose-dependent manner the inhibitory effects of VIP and PACAP (Fig. 4B) . In contrast, calphostin C, a PKC inhibitor, does not reverse the inhibitory effects of the two neuropeptides (Fig. 4B) . These results suggest that the inhibitory effects of VIP and PACAP in both AICD and FasL expression are mediated through increases in intracellular cAMP.
VIP and PACAP inhibit c-myc expression in activated T cell hybridomas
FasL expression during AICD requires the activation of several transcription factors. Previous studies indicated that c-myc regulates the expression of FasL and subsequent apoptosis in some systems, including T cells. To determine whether VIP and PACAP regulate c-myc expression in T cell hybridomas, we analyzed the expression of c-myc by Northern and Western blots. VIP and PACAP inhibit anti-CD3-induced c-myc expression at both protein and mRNA levels (Fig. 5) .
VIP and PACAP inhibit NF-B binding to the FasL promoter
Although the FasL promoter contains a complex array of transactivating binding sites, NF-B, NF-AT, and the FLRE sites appear to be essentials for maximal FasL transcription in T cells stimulated through the TCR/CD3 complex (37) . We investigated whether VIP/PACAP affect NF-B nuclear translocation by EMSA. Treatment of 2B4.11 cells with anti-CD3 Abs led to strong NF-B binding, and VIP and PACAP inhibited this binding (Fig.  6A, left panel) . The specificity of the NF-B binding was evident by the complete displacement with a 50-fold excess of unlabeled homologous oligonucleotide (NF-B) (Fig. 6A, middle panels) . In contrast, a 50-fold excess of unlabeled nonhomologous oligonucleotide (NF-AT) had no effect (Fig. 6A, middle panels) . Ab supershift experiments indicated the presence of both p50 and p65 in the NF-B complex, whereas no supershift was observed with an irrelevant Ab (anti-NF-ATp) (Fig. 6A, right panel) .
VIP and PACAP inhibit activation-dependent phosphorylation of I-B␣ and nuclear translocation of the p65 subunit of NF-B
In unstimulated T cells, NF-B is sequestered in the cytoplasm complexed to I-B (reviewed in Ref. 38) . Stimulation through TCR/CD3 results in the phosphorylation and proteolytic degradation of I-B, and subsequent translocation of NF-B to the nucleus. To determine whether VIP and PACAP act on I-B␣, we examined the cytoplasmic levels of I-B␣ by Western blot. In anti-CD3-stimulated cells, the time-dependent I-B␣ degradation is apparent (Fig. 6, B and C) . The decrease in cytoplasmic I-B␣ levels is paralleled by an increase in I-B␣ phosphorylation (Fig.  6C, lower panel) . Treatment with VIP or PACAP blocks the activation-mediated phosphorylation and subsequent degradation of I-B␣ (Fig. 6, B and C) .
Because NF-B activation involves its nuclear translocation, we measured the levels of p65 protein in cytoplasm and nucleus. As expected, anti-CD3 treatment decreased the level of p65 in cytoplasm and increased the p65 levels in the nucleus (Fig. 6B) . Treatment with VIP or PACAP abolished the change in nuclear and cytoplasmic p65 levels (Fig. 6B) . This indicates that VIP and PACAP inhibit the activation-induced nuclear translocation of p65, which is consistent with the inhibition of I-B␣ phosphorylation and degradation. Neither anti-CD3 treatment by itself, nor in combination with VIP/PACAP, affected nuclear and cytoplasmic p50 levels (Fig. 6B) . The equal levels of p50 also serve as loading controls (Fig. 6B) .
Because phosphorylation of I-B by the I-B kinases (IKK) is crucial for NF-B activation, we investigated whether VIP and PACAP regulate IKK␣ activity by using an in vitro kinase assay. Stimulation of 2B4.11 cells with anti-CD3 Abs results in a timedependent increase in IKK␣ activity (Fig. 6D) . VIP and PACAP inhibit activation-induced IKK␣ activity (Fig. 6D) .
VIP and PACAP inhibit activation-induced nuclear translocation of NF-ATp and its binding to the FasL promoter
NF-AT was reported to play a critical role in FasL up-regulation following TCR stimulation (19, 22, 29, 33) . Induction of FasL mRNA is prevented by CsA, an immunosuppressive drug that inhibits CaN activity. CaN dephosphorylates NF-AT and induces its nuclear translocation. NF-ATp has been directly implicated in FasL transcription by its binding to a transactivating site in the FasL promoter (19, 22) , and by the fact that anti-TCR-induced up-regulation of FasL in vivo is impaired in NF-ATp knockout mice (39) . To determine whether VIP and PACAP regulate NF-ATp binding to the FasL promoter, we used electromobility shift assays with probe derived from the distal NF-AT site in the FasL promoter. Stimulation of 2B4.11 cells led to strong NF-AT binding, and VIP and PACAP reduced this binding, similar to CsA (Fig. 7A, left panel) . The binding specificity was confirmed by using homologous (NF-AT) or nonhomologous (NF-B and cAMP response element) oligonucleotides as competitors (Fig. 7A, middle panel) . The NF-AT complexes were supershifted by an anti-NF-ATp Ab, but not by anti-p65 Abs (Fig. 7A, right panel) .
To determine whether VIP and PACAP inhibit the nuclear translocation of NF-ATp, we performed Western blots with nuclear and cytoplasmic extracts (Fig. 7B) . As expected, in unstimulated 2B4.11 cells NF-ATp was located preferentially in the cytoplasm (Fig. 7B) . However, anti-CD3 stimulation resulted in the reduction of cytoplasmic NF-ATp, and the increase in nuclear NF-ATp (Fig.  7B ). VIP and PACAP inhibit NF-ATp nuclear translocation, and block the decrease in cytoplasmic NF-ATp at all times assayed (Fig. 7B) . However, the inhibition of NF-AT nuclear translocation was not due to an inhibition of CaN, because VIP and PACAP did not affect CaN activity (Fig. 7C) . As expected, CsA led to a dramatic decrease in CaN activity (Fig. 7C ).
VIP and PACAP inhibit Egr2 and Egr3 expression and their subsequent binding to the FLRE site of the FasL promoter
Mittelstadt and Ashwell (25, 26) identified a FLRE in the FasL promoter, which confers the majority of TCR-inducible FasL promoter activity in 2B4.11 cells and in human T cell blasts. FLRE is a binding site for Egr1, Egr2, and Egr3, members of the early growth-response family of transcriptional factors. The effect of VIP and PACAP on Egr1, 2, and 3 binding to the FLRE site was assessed by EMSA. As previously described (25, 26) , nuclear extracts from unstimulated 2B4.11 T cells exhibit only a nonspecific band (ns) (Fig. 8A, lane 1) . In contrast, extracts from anti-CD3-stimulated cells exhibit two specific bands, a major, lower mobility band (corresponding to Egr1 and Egr2 binding) (25, 26) , and a minor, higher mobility band (corresponding to Egr3 binding) (25, 26) (Fig. 8A, lane 2) . VIP and PACAP, as well as CsA, prevent the appearance of the minor band, without obvious effects on the major band (Fig. 8A, lanes 3-5) .
The composition of the FLRE-binding complexes was determined by supershift assays. In anti-CD3-stimulated cells, the major band is supershifted primarily by anti-Egr1, and to a lesser extent by antiEgr2, whereas the minor band is supershifted completely by anti-Egr3 (Fig. 8B) . No supershift was observed with anti-NF-ATp (an irrelevant Ab). Following VIP or PACAP treatment, the minor band disappears, and the major band is supershifted completely by anti-Egr1 (no supershift is evident for anti-Egr2) (Fig. 8B) . Same results were 7 cells) were incubated with medium alone (unstimulated), or activated with anti-CD3 mAbs in the presence or absence of VIP (10 Ϫ8 M), PACAP (10 Ϫ8 M), or CsA (100 ng/ml). Nuclear extracts (3 h) were prepared and NF-AT binding was assessed by EMSA using a radiolabeled oligonucleotide containing the NF-AT site of the murine FasL promoter. Middle panel, Specificity was assessed by the addition of 50-fold excess of unlabeled homologous (NF-AT) or nonhomologous (NF-B and cAMP response element) oligonucleotides to nuclear extracts (Comp). Right panel, Identification of the proteins bound to the NF-AT site using supershift analysis. Nuclear extracts were incubated with polyclonal Abs (1 g) against p65 or NF-ATp for 20 min before adding the probe. Upper arrow indicates the supershifted NF-ATp-specific bands. Similar results were observed in three independent experiments. B, VIP and PACAP inhibit activation-induced NF-ATp nuclear translocation. The 2B4.11 cells (2 ϫ 10 7 cells) were incubated with medium alone (unstimulated), or activated with anti-CD3 mAbs in the presence or absence of VIP (10 Ϫ8 M), PACAP (10 Ϫ8 M), or CsA (100 ng/ml). At different times (1 h for left panels), cytosolic and nuclear proteins were extracted, and Western blot analysis was performed for NF-ATp. One representative experiment of three is shown. C, VIP and PACAP do not affect CaN activity. The 2B4.11 cells (2 ϫ 10 7 cells) were incubated with medium alone (unstimulated), or activated with anti-CD3 mAbs in the presence or absence of VIP (10 Ϫ8 M), PACAP (10 Ϫ8 M), or CsA (100 ng/ml) for 30 min. Cytosolic proteins were extracted and CaN activity was assayed, as described in Materials and Methods. Results are the mean Ϯ SD of three different experiments performed in duplicate. obtained for CsA treatment (Fig. 8B) . Therefore, the FLRE-binding complexes in stimulated cells consist of Egr1, 2, and 3, and treatment with VIP or PACAP leads to complexes consisting only of Erg1.
Next we investigated whether VIP and PACAP regulate Egr1, Egr2, and Egr3 expression. The 2B4.11 cells were stimulated with immobilized anti-CD3 Abs in the presence or absence of VIP, PACAP, or CsA, and expression of the three Egr proteins was detected by Western blot. The Egr1 protein is constitutively expressed, and neither VIP/PACAP nor CsA affects its expression. However, Egr2 and Egr3 protein levels were increased after anti-CD3 stimulation, and VIP, PACAP, and CsA dramatically reduced both Egr2 and Egr3 (Fig. 8C) . The inhibitory effect on Egr2 and Egr3 was exerted at the mRNA level, because VIP, PACAP, and CsA reduced both egr2 and egr3 steady state mRNA levels (Fig. 8C) .
Because induction of Egr2 and Egr3 was sensitive to CsA (25, 26) (Fig. 8C) , the expression of the egr2 and egr3 might be dependent on NF-AT. In fact, a transcriptionally active NF-AT site was identified in the egr3 promoter (31) . Therefore, we investigated whether VIP and PACAP regulate NF-AT binding to the egr3 promoter by using the NF-AT site from the erg3 promoter as a specific probe. Similar to CsA, VIP and PACAP inhibit the binding to the egr3/NF-AT site (Fig. 8D, left panel) . The binding specificity was confirmed by using homologous (NF-AT) or nonhomologous (NF-B) oligonucleotides as competitors (Fig. 8D,  middle panel) . Supershift assays indicate that the complex binding to the egr3/NF-AT site consists of NF-AT. An irrelevant Ab (antip65) was used as control (Fig. 8D, right panel) . These results suggest that the inhibition of Egr3, and possibly Egr2, by VIP/ PACAP is mediated, at least partially, through the inhibition of NF-AT.
Involvement of VPAC2 and cAMP/PKA in the inhibitory effects of VIP and PACAP on c-myc, NF-B, NF-AT, and Egr2/3
Because the inhibitory effect of VIP/PACAP on FasL expression and subsequent AICD in 2B4.11 cells is mediated through VPAC2 and cAMP, we determined the effects of PACAP 6 -38 , a VPAC2 antagonist, and of the PKA inhibitor H89 on the changes induced by VIP in c-myc, NF-B, NF-AT, and Egr2/3. The receptor antagonist and the PKA inhibitor reversed the effect of VIP on c-myc, and forskolin, a cAMP inducer, mimicked the effect of VIP (Fig.  9A) . Same conclusions were reached for NF-B binding, p65 and I-B␣ cytoplasmic levels, and IKK␣ activity (Fig. 9B) . In addition, the receptor antagonist and H89 reversed the effect of VIP, and forskolin mimicked the effect of VIP on NF-AT binding and NF-AT levels in nuclear extracts (Fig. 9C) . A similar conclusion was reached for Egr2 and 3 both in supershift experiments and Western blots (Fig. 9D) . These experiments indicate that, similar to the effects on FasL expression and apoptosis, the inhibitory effects of VIP on the expression of c-myc, Egr2 and 3, the nuclear translocation of p65 and NF-ATp, and the IKK␣ kinase activity are mediated through the VPAC2 receptor and increases in intracellular cAMP.
Discussion
A major mechanism for the maintenance of immune homeostasis is the AICD that affects activated and proliferating T cells upon restimulation through the TCR. AICD, particularly in CD4 ϩ T cells, is mediated through Fas/FasL interactions, leading to the activation of the intracellular Fas/Fas-associated death domain protein/caspase cascade, and ultimately to the apoptotic death of the Fas-bearing target. In contrast to Fas, which is expressed constitutively in peripheral T cells, and is up-regulated upon activation, FasL expression is induced following TCR stimulation (reviewed in Refs. 14 and 15). Regulation of FasL expression has significant physiological consequences, and therefore, is of considerable interest.
We reported previously that two neuropeptides, VIP and PACAP, protect peripheral T cells from AICD in vitro and in vivo, through the inhibition of FasL expression (13) . In this study, we investigated the molecular mechanisms involved in the VIP/ PACAP regulation of FasL expression in T cell hybridomas. We established that the protective effect against AICD and the inhibition of FasL expression are mediated through the specific VPAC2 receptor and involve cAMP as the secondary messenger. Electromobility shift and supershift assays indicate that VIP/PACAP reduce the specific DNA binding of several transcriptional factors, i.e., NF-B, NF-AT, and Egr2 and 3. VIP/PACAP block the nuclear translocation of both NF-B and NF-ATp, and inhibit the expression of c-myc, Egr2, and Egr3. The effects of VIP/PACAP were mimicked by forskolin, and reversed by the PKA inhibitor H89 and by the VPAC2 receptor antagonist, confirming the involvement of VPAC2 and of intracellular cAMP as mediators for the regulation of FasL expression by VIP and PACAP (Fig. 10) .
Although the exact mechanism by which c-myc regulates FasL expression is not clear, c-myc is required for AICD in T cells (16, 18, 40) . Recently, the TCR-induced activity of the FasL promoter was shown to require functional Myc-Max heterodimers, even in the absence of specific Myc-binding motifs in the FasL promoter (41) . Our studies indicate that VIP/PACAP inhibit c-Myc expression in the TCR-stimulated 2B4.11 hybridoma, at both protein and mRNA level through a cAMP-dependent pathway. The relationship between cAMP and c-myc expression has been previously documented (42, 43) . However, the intracellular pathways connecting the cAMP/PKA to c-myc expression in T cells are not understood. In a transformed myeloid cell line, cAMP was shown to induce the sequestration of E2F1, a transcriptional factor required for the expression of c-myc, and to prevent G 1 cell cycle progression through the down-regulation of cyclin D1 and cdk4 (42) .
Studies with the FasL promoter have established the presence of several sites important in transcription, i.e., NF-B (21, 23, 24) , NF-AT (19, 20) , AP-1 (37), and Egr2/3 specific binding sites (25, 26) . The relative functional importance of these sites might differ among species. For example, mutations in the Erg binding site of the human FasL promoter abolish its activity (26) , whereas resulting only in 50 -60% reduction for the murine promoter (37) . However, mutations in both the Egr-and the B1-binding sites silence the murine FasL promoter (37) . These results suggest that NF-B and Egr2/3 are the most important transcriptional factors for the expression of murine FasL.
Our results indicate that VIP and PACAP reduce NF-B binding to the B1 site, and that the inhibitory effect is mediated through VPAC2 and intracellular cAMP. The inhibition of NF-B binding is associated with a reduction in p65 nuclear translocation. p65 is retained in the cytoplasm due to the stabilization of I-B. As previously demonstrated for macrophages (44, 45) , VIP and PACAP inhibit I-B␣ phosphorylation. This is accomplished through an inhibitory effect on the IKK␣, a kinase specific for I-B. Although the link between cAMP and IKK␣ is not elucidated, one possibility is that mitogen-activated protein kinase kinase 1 (MEKK1), which was shown to synergize with NF-B-inducing kinase in the activation of IKK␣ and ␤ (46, 47) , is inhibited by increased levels of intracellular cAMP. We reported recently that VIP and PACAP inhibit MEKK1 in macrophages through a cAMP-dependent mechanism (48) . In addition, increases in cAMP lead to cAMP regulatory element binding protein (CREB) phosphorylation and nuclear translocation. CREB has a high avidity for the CREBbinding protein (CBP), a nuclear cofactor required for NF-B transcriptional activity (49) . Because CBP is present in limiting amounts, its sequestration by CREB leads to a reduction in the transcriptional activity of NF-B. Fig. 6 . Middle panels, After 1-h incubation, nuclear and cytoplasmic extracts were subjected to SDS-PAGE under reducing conditions, and probed with Abs against p50 and p65 (nuclear extracts) or I-B␣ (cytosolic fraction). Lower panel, After 10 min, IKK␣ activity was analyzed with I-B␣ as substrate by using an in vitro kinase assay, as described in Materials and Methods. One representative experiment of three is shown. C, Upper panel, After 2-h incubation, NF-AT binding was analyzed by EMSA, as described in Fig. 7 . Lower panel, After 1-h incubation, expression of NF-ATp in the cytoplasmic fraction was analyzed by Western blot. One representative experiment of three is shown. D, Upper panel, After 3-h incubation, the composition of the complex binding to the FLRE site was analyzed by gel supershift, by incubating nuclear extracts with an anti-Egr1 Ab for 20 min before adding the FLRE probe. Bands corresponding to Egr2, Egr3, and a nonspecific (ns) band are indicated. Arrow indicates the supershifted Egr1-specific band. Similar results were observed in three independent experiments. Lower panels, After 1-h incubation, the expression of Egr2 and Egr3 proteins was analyzed by Western blot. One representative experiment of three is shown.
Our results indicate that VIP and PACAP also inhibit NF-AT binding, and NF-ATp translocation to the nucleus, and that the effects on NF-AT are mediated through VPAC2 and intracellular cAMP. FasL expression was reported to be sensitive to CsA, and NF-AT sites were indeed identified in the FasL promoter (19, 20) . NF-ATp nuclear translocation and transcriptional activity depends on its dephosphorylation by CaN (50) . Therefore, CaN represents one of the potential targets for the inhibitory effect of VIP/PACAP on NF-ATp translocation. However, in contrast to CsA, VIP and PACAP did not affect CaN activity. The cAMP-dependent pathway initiated through VPAC2 by VIP and PACAP could affect NF-AT activity in several ways. A direct PKA-mediated phosphorylation of NF-AT, which results in a decrease in transcriptional activity, was reported recently (51) . In addition, previous reports indicated the generation of cAMP-dependent transcriptional inhibitors for NF-AT (52) . Finally, because both NF-AT and NF-B require the coactivator CBP for transcriptional activity (53) , sequestration of CBP by CREB following cAMP induction will interfere with both these transcriptional factors.
Our results are in agreement with Hsu et al. (54) , who indicated that cAMP inhibits FasL expression by suppressing NF-B, but contradict a previous report by Lee et al. (55) , who reported no changes in NF-AT and NF-B binding by cAMP analogues. This might be due to the difference in the oligonucleotides used as probes, i.e., Lee et al. used a human IL-2 enhancer NF-AT site and an Ig -chain NF-B site, whereas we used the specific proximal NF-B and NF-AT sites from the murine FasL promoter (28, 33) .
Finally, our results indicate that VIP and PACAP inhibit Erg2 and 3 binding to the FLRE site, and inhibit the expression of the inducible Egr2 and 3 factors at protein and mRNA level. In contrast, Egr1, which is constitutively expressed in the 2B4.11 cells, is not affected by VIP or PACAP. Egr2 and 3 emerged recently as probably the most important transcriptional factors for FasL expression (25, 26) . Induction of both Erg2 and 3 is CsA sensitive, suggesting that NF-AT participates in the expression of the erg2/3 genes (26). Therefore, the effect of VIP/PACAP on Egr2/3 synthesis is probably mediated, at least partially, through the reduction in NF-AT translocation. However, at the present time, a direct connection between cAMP-dependent events and Erg2/3 expression cannot be eliminated.
Although neuropeptides such as VIP and PACAP were initially characterized as antiinflammatory agents, a more accurate functional description is as endogenous modulators of the immune response. The inhibition of activation-induced T cell apoptosis through mechanisms described in this study is in agreement with the proposed immunomodulatory role. During an immune response, mechanisms must be in place to allow the survival of a small number of activated T cells and their differentiation into memory cells. Naive T cells, although Fas ϩ , are apoptosis resistant, and upon activation switch to an apoptosis-sensitive phenotype during the proliferative stage (14) . Through the down-regulation of FasL expression, VIP and PACAP might favor the local generation of apoptosis-resistant memory T cells. Another physiological relevance for the inhibition of FasL expression by VIP and PACAP is the effect on Fas/FasL-dependent cell-mediated cytotoxicity, especially in organ-specific autoimmune diseases in which Fas/FasL-dependent cytotoxicity against bystander targets contributes to tissue destruction.
